Kelsey Goodwin
Stock Analyst at Piper Sandler
(3.79)
# 706
Out of 4,969 analysts
23
Total ratings
57.89%
Success rate
9.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $23.35 | -10.06% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $22.90 | +83.41% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $39.66 | +89.11% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $19.17 | +87.79% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $27.76 | +98.13% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $6.51 | +68.97% | 1 | Aug 19, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $112 | $78.51 | +42.67% | 3 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $11.87 | +203.29% | 1 | Aug 19, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.47 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $3.32 | +140.96% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.88 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $70.23 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $35.73 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.19 | - | 1 | Oct 31, 2022 |
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $23.35
Upside: -10.06%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $22.90
Upside: +83.41%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $39.66
Upside: +89.11%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $19.17
Upside: +87.79%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $27.76
Upside: +98.13%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $6.51
Upside: +68.97%
Nuvalent
Aug 19, 2025
Initiates: Overweight
Price Target: $112
Current: $78.51
Upside: +42.67%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $11.87
Upside: +203.29%
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.47
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $3.32
Upside: +140.96%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.88
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $70.23
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $35.73
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.19
Upside: -